IL-8 as a circulating cytokine: Induction by recombinant tumour necrosis factor-alpha

N. Sheron*, R. Williams

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

40 Citations (Scopus)


Tumour necrosis factor-alpha (TNF-α) is a pivotal cytokine at the centre of a cascade of cytokines and inflammatory mediators which modulate the host response to infection and trauma, and in particular the metabolic changes resulting in shock and subsequent multi-organ failure. The cytokine IL-8-predominantly an activator and chemotactic factor for circulating polymorphonuclear neutrophil leucocytes-is produced in response to TNF-α in vitro, and high circulating levels of IL-8 are found in septic primates. We have studied the release of IL-8 into the circulation of subjects with chronic hepatitis B undergoing a 10 week pilot trial of recombinant TNF-α (rTNF-α) therapy in doses of 15-100 μg/m2. A marked dose-dependent increase in plasma IL-8 levels was seen commencing at 30-60 min after the start of rTNF-α infusion and peaking between 2 and 3 h (mean peak level 4300 ng/l). The temporal pattern of IL-8 production exactly echoed that of IL-6, another component of the cytokine cascade, but peak plasma levels of IL-8 were up to 17 times higher than those of IL-6. This study confirm's in vitro data suggesting that IL-8 is a component of the acute circulating cytokine cascade with a potential role in the modulation of the acute immune and metabolic response to infection and trauma.

Original languageEnglish
Pages (from-to)100-103
Number of pages4
JournalClinical and Experimental Immunology
Issue number1
Publication statusPublished - 1992
Externally publishedYes


  • hepatitis B
  • IL-8
  • septic shock
  • tumour necrosis factor


Dive into the research topics of 'IL-8 as a circulating cytokine: Induction by recombinant tumour necrosis factor-alpha'. Together they form a unique fingerprint.

Cite this